Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Cash from Operations (2016 - 2025)

Northwest Biotherapeutics' Cash from Operations history spans 16 years, with the latest figure at 14764000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 14764000.0 for Q4 2025, up 26.84% from a year ago — trailing twelve months through Dec 2025 was 44763000.0 (up 21.49% YoY), and the annual figure for FY2025 was 44763000.0, up 21.49%.
  • Cash from Operations for Q4 2025 was 14764000.0 at Northwest Biotherapeutics, down from 13893000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 6688000.0 in Q2 2025 to a low of 20181000.0 in Q4 2024.
  • The 5-year median for Cash from Operations is 12686500.0 (2022), against an average of 12324550.0.
  • The sharpest move saw Cash from Operations tumbled 129.83% in 2022, then surged 58.71% in 2025.
  • Year by year, Cash from Operations stood at 11246000.0 in 2021, then grew by 21.31% to 8849000.0 in 2022, then crashed by 91.64% to 16958000.0 in 2023, then dropped by 19.01% to 20181000.0 in 2024, then increased by 26.84% to 14764000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 14764000.0, 13893000.0, and 6688000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.